Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$10.59 USD
-1.70 (-13.80%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $10.53 -0.06 (-0.52%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
IOVA 10.59 -1.70(-13.80%)
Will IOVA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for IOVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IOVA
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates
IOVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates
Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
Other News for IOVA
Stifel Nicolaus Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...
Iovance Biotherapeutics’ Strong Q3 2024 Performance
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript
Optimistic Outlook for Iovance Biotherapeutics with Strong Q3 Performance and Growth Potential